Scientists map immune response in lung cancer fight
NCT ID NCT04432142
Summary
This study aims to understand how the immune system changes in people with stage III non-small cell lung cancer while they receive standard treatment. Researchers will observe 45 patients undergoing combined chemotherapy and radiation, followed by a drug called durvalumab. The goal is to learn how these treatments affect immune cells, which could help doctors predict which patients will benefit most from similar treatments in the future.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Maastricht Radiation Oncology (MAASTRO clinic)
Maastricht, 6229 ET, Netherlands
Conditions
Explore the condition pages connected to this study.